The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.
 
Melissa Amber Burgess
Consulting or Advisory Role - EMD Serono
Travel, Accommodations, Expenses - SpringWorks Therapeutics
 
Vanessa Bolejack
No Relationships to Disclose
 
Scott Schuetze
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - AB Science (Inst); Adaptimmune (Inst); Amgen (Inst); BioMed Valley Discoveries (Inst); Blueprint Medicines (Inst); CytRx Corporation (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Blueprint Medicines
 
Brian Andrew Van Tine
Consulting or Advisory Role - Caris Life Sciences; CytRx Corporation; EMD Serono; Johnson & Johnson; Lilly/ImClone; Novartis; Plexxikon; Threshold Pharmaceuticals
Speakers' Bureau - Caris Life Sciences; Johnson & Johnson; Lilly; Novartis
Research Funding - Merck; Pfizer
Expert Testimony - Me1 Patient
 
Steven Attia
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); BTG (Inst); CBA Pharma (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); Genmab (Inst); Gradalis (Inst); Immune Design (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Philogen (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - Immune Design
 
Richard F. Riedel
Employment - Biotech Prosthetic Orthotics of North Carolina (I); Limbguard (I)
Leadership - Biotech Prosthetic Orthotics of North Carolina (I); Limbguard (I)
Stock and Other Ownership Interests - Biotech Prosthetic Orthotics of North Carolina (I); Limbguard (I)
Consulting or Advisory Role - Bayer; Bayer; Daiichi Sankyo; Eisai; GlaxoSmithKline; Ignyta; Lilly; Loxo; Merck; NanoCarrier; Novartis
Research Funding - AADi (Inst); Agios (Inst); Arog (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Ignyta (Inst); Immune Design (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); NanoCarrier (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - PandoNet - Limbguard (I)
Travel, Accommodations, Expenses - Daiichi Sankyo; EMD Serono; Ignyta; Janssen; NanoCarrier
 
James S Hu
Stock and Other Ownership Interests - Biogen
Honoraria - Eisai
Consulting or Advisory Role - Eisai
Speakers' Bureau - Eisai
Travel, Accommodations, Expenses - Eisai
 
Lara Emily Davis
Consulting or Advisory Role - Epizyme; Immune Design; Loxo
 
Scott H. Okuno
No Relationships to Disclose
 
Dennis A. Priebat
No Relationships to Disclose
 
Sujana Movva
Consulting or Advisory Role - Genmab
Research Funding - Novartis (Inst); Takeda (Inst)
 
Damon R. Reed
Consulting or Advisory Role - Epizyme; Loxo; Shire
 
Sandra P. D'Angelo
Consulting or Advisory Role - Amgen; EMD Serono; GlaxoSmithKline; Immune design; Incyte; Merck; Nektar
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); EMD Serono (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst)
Patents, Royalties, Other Intellectual Property - Phase II study of TVEC + pembrolizumab in sarcoma
Travel, Accommodations, Expenses - Adaptimmune; EMD Serono; Nektar
 
Alexander J. Lazar
Employment - GE Healthcare (I)
Leadership - Archer; Beta Cat Pharmaceuticals
Stock and Other Ownership Interests - Archer; Beta Cat Pharmaceuticals
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Janssen Oncology; Novartis
Consulting or Advisory Role - GE Healthcare; Illumina; Novartis
Research Funding - AstraZeneca; MedImmune; Novartis; Roche
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
Emily Zhi-Yun Keung
No Relationships to Disclose
 
Denise K. Reinke
Research Funding - Bayer (Inst); SARC: Sarcoma Alliance for Research though Collaboration (Inst); Tesaro (Inst); Threshold Pharmaceuticals (Inst)
 
Laurence H. Baker
No Relationships to Disclose
 
Robert G. Maki
Honoraria - Lilly; Springer; Wiley
Consulting or Advisory Role - AADi; American Board of Internal Medicine (ABIM); Arcus Ventures; Bayer; Deciphera; Foundation Medicine; Janssen Scientific Affairs; Karyopharm Therapeutics; Lilly/ImClone; SARC: Sarcoma Alliance for Research though Collaboration; TRACON Pharma
Research Funding - Abbvie (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); FORMA Therapeutics (Inst); Immunocore (Inst); Lilly (Inst); Pfizer (Inst); Presage Biosciences (Inst); Regeneron (Inst); TRACON Pharma (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Springer and Wiley: Books for contributions I have made to the published texts; Uptodate: I write and edit chapters for their online text book.
Travel, Accommodations, Expenses - Bayer; TRACON Pharma
 
Shreyaskumar Patel
Consulting or Advisory Role - CytRx Corporation; EMD Serono; Epizyme; Immune Design; Janssen; Lilly; Michael J. Hennessy Company; Novartis; OncLive; PharmaMar
Research Funding - Bavarian Nordic; Blueprint Medicines; Eisai; Janssen
Patents, Royalties, Other Intellectual Property - UpToDate
 
Hussein Abdul-Hassan Tawbi
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst)